Key clinical point: Right ventricular systolic pressure (RVSP) increased significantly following dasatinib therapy in some patients with chronic-phase chronic myeloid leukemia (CML-CP), leading to dasatinib-induced pulmonary arterial hypertension (D-PAH) and consequent therapy discontinuation.
Major finding: During a median of 36.2 months of dasatinib therapy, mean RSVP increased significantly and gradually ( P less than .001). Overall, 56 patients had RVSP over 40 mmHg, of which 51.8% of patients were diagnosed with D-PAH with clinical symptoms, all ultimately switching to other tyrosine kinase inhibitors.
Study details : Findings are from an analysis of a cohort of 451 patients with CML-CP who underwent 2D-echocardiography at least once at baseline and/or during dasatinib therapy (mean dose, 85 mg/day) as frontline (n=196) and subsequent line (n=255).
Disclosures: This study was funded by Korea Leukemia Bank. The authors declared no conflicts of interest.
Source: Lee SE et al. Cancer Med. 2021 Feb 15. doi: 10.1002/cam4.3588 .